https://www.cbc.ca/news/canada/saskatchewan/vido-vaccine-phase-1-trial-preliminary-results-1.6076830
Interim data from Phase 1 clinical trials has demonstrated VIDO's COVAC-2 vaccine is safe and well tolerated, the university said Wednesday news release.
Create an account
or login to join the discussion